用于既往经表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)治疗时或治疗后出现疾病进展,并且经检测确认存在EGFR T790M突变阳性的局部晚期或转移性非小细胞性肺癌(NSCLC)成人患者的治疗。
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China
Shanghai Chest Hospital, Shanghai, Shanghai, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.